Caribou Biosciences Inc (CRBU) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Caribou Biosciences Inc   (NASDAQ: CRBU)


Caribou Biosciences Inc's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Caribou Biosciences Inc's ROI in the first quarter of 2026?
Caribou Biosciences Inc recorded a cumulative net loss of $-133 million during 12 months ending in the first quarter of 2026, resulting in a negative return on investment (ROI) of -83.49%.

Within the Healthcare sector 618 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2025 from 2847 to 3864.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM -46 % -42.64 % -38.24 % -33.7 % -22.74 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 129 150 167 192 245
Return On Investment (TTM) -83.49 % -78.57 % -70.88 % -63.67 % -50.04 %
CRBU's Overall Ranking # 3864 # 2847 # 3412 # 3413 # 3484
Seq. Investment Change TTM -15.36 % -14.97 % -14.07 % -12.69 % -10.09 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -133 -148 -157 -164 -148

CRBU Company Profile >> Back to CRBU Roi Comparisons >> See Annual CRBU Return On Investment



Return On Investment CRBU's Ranking
Within: No.
Industry # 91
Sector # 619
Overall # 3864

Return On Investment Statistics
High Average Low
-6.01 %
-38.17 %
-82.6 %
(Mar 31 2022)   (Mar 31 2026)



  News about Caribou Biosciences Inc Return on Investment ROI

Caribou Biosciences Strengthens Clinical Development with Appointment of Dr. Tina Albertson as Chief Medical Officer,

August 12, 2024

Caribou Biosciences Appoints Highly-Experienced Hematologist and Oncologist, Dr. Tina Albertson, as Chief Medical Officer
Berkeley, Calif., Aug. 12, 2024 - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, has recently announced the appointment of Dr. Tina Albertson, MD, PhD, as the new chief medical officer. With an impressive background in leading clinical drug development of cellular therapies and biologics spanning over 15 years, Dr. Albertson brings a wealth of experience to Caribou Biosciences. In her new role, she will oversee the strategic leadership of clinical, regulatory, and medical functions, as well as provide operational leadership for the company s four clinical programs focused on hematologic malignancies and autoimmune diseases. Dr. Albertson will report directly to Caribou s president and CEO, Dr. Rachel Haurwitz.
Caribou Biosciences, being a clinical-stage CRISPR genome-editing biopharmaceutical company, is at the forefront of developing innovative therapies for serious diseases. The appointment of Dr. Albertson as chief medical officer is a significant move for the company, highlighting its commitment to advancing its clinical pipeline and reinforcing its position as a leader in the healthcare sector.





Financial Statements
Caribou Biosciences Inc's I. Quarter Investments $ 129 Millions CRBU's Balance sheet
Caribou Biosciences Inc's I. Quarter Income $ -25 Millions Quarterly CRBU's Income Statement
CRBU's Income by Division See CRBU's Income by Division


CRBU Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 150 283 404 346 417
Y / Y Investment Growth -46.95 % -30.02 % 16.86 % -17.02 % -
Net Income in Millions -148 -149 -102 -99 -67
Y / Y Net Income Growth - - - - -
Annual Return On Investment -98.78 % -52.75 % -25.27 % -28.76 % -16.07 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CRBU's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CRBU's Competitors
Subscribers only: Roi for Caribou Biosciences Inc's Suppliers
Subscribers only: Return On Investment for CRBU's Customers

Other Ratios
CRBU's Roa CRBU's Inventory Turnover Ratio CRBU's Growth Rates CRBU's Dividend Statistics
CRBU's Profitability Ratios CRBU's Asset Turnover Ratio CRBU's Dividend Growth
CRBU's Roe CRBU's Valuation Ratios CRBU's Financial Strength Ratios CRBU's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI

Date modified: 2026-08-29T17:44:49+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.